Nycomed strengthens its osteoporosis portfolio
. - Licensing agreement for EX101 (effervescent alendronate) with EffRx, Inc. - First effervescent formulation of alen…
. - Licensing agreement for EX101 (effervescent alendronate) with EffRx, Inc. - First effervescent formulation of alen…
In the first six months of 2008, Nycomed's adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 mill…